140 related articles for article (PubMed ID: 15162210)
1. (1R,4S,5R)-3-Fluoro-1,4,5-trihydroxy-2-cyclohexene-1-carboxylic acid: the fluoro analogue of the enolate intermediate in the reaction catalyzed by type II dehydroquinases.
Frederickson M; Roszak AW; Coggins JR; Lapthorn AJ; Abell C
Org Biomol Chem; 2004 Jun; 2(11):1592-6. PubMed ID: 15162210
[TBL] [Abstract][Full Text] [Related]
2. Nanomolar competitive inhibitors of Mycobacterium tuberculosis and Streptomyces coelicolor type II dehydroquinase.
Prazeres VF; Sánchez-Sixto C; Castedo L; Lamb H; Hawkins AR; Riboldi-Tunnicliffe A; Coggins JR; Lapthorn AJ; González-Bello C
ChemMedChem; 2007 Feb; 2(2):194-207. PubMed ID: 17245805
[TBL] [Abstract][Full Text] [Related]
3. Rational design, synthesis, and evaluation of nanomolar type II dehydroquinase inhibitors.
Payne RJ; Peyrot F; Kerbarh O; Abell AD; Abell C
ChemMedChem; 2007 Jul; 2(7):1015-29. PubMed ID: 17487900
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design, synthesis, and biological evaluation of inhibitors of Mycobacterium tuberculosis type II dehydroquinase.
Sánchez-Sixto C; Prazeres VF; Castedo L; Lamb H; Hawkins AR; González-Bello C
J Med Chem; 2005 Jul; 48(15):4871-81. PubMed ID: 16033267
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of potent ene-yne inhibitors of type II dehydroquinases as tuberculosis drug leads.
Tran AT; Cergol KM; West NP; Randall EJ; Britton WJ; Bokhari SA; Ibrahim M; Lapthorn AJ; Payne RJ
ChemMedChem; 2011 Feb; 6(2):262-5. PubMed ID: 21275049
[No Abstract] [Full Text] [Related]
6. Nanomolar inhibition of type II dehydroquinase based on the enolate reaction mechanism.
Toscano MD; Payne RJ; Chiba A; Kerbarh O; Abell C
ChemMedChem; 2007 Jan; 2(1):101-12. PubMed ID: 17068841
[TBL] [Abstract][Full Text] [Related]
7. A prodrug approach for improving antituberculosis activity of potent Mycobacterium tuberculosis type II dehydroquinase inhibitors.
Tizón L; Otero JM; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Ainsa JA; Castedo L; González-Bello C
J Med Chem; 2011 Sep; 54(17):6063-84. PubMed ID: 21780742
[TBL] [Abstract][Full Text] [Related]
8. The two types of 3-dehydroquinase have distinct structures but catalyze the same overall reaction.
Gourley DG; Shrive AK; Polikarpov I; Krell T; Coggins JR; Hawkins AR; Isaacs NW; Sawyer L
Nat Struct Biol; 1999 Jun; 6(6):521-5. PubMed ID: 10360352
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and structural studies on potent biaryl inhibitors of type II dehydroquinases.
Payne RJ; Riboldi-Tunnicliffe A; Kerbarh O; Abell AD; Lapthorn AJ; Abell C
ChemMedChem; 2007 Jul; 2(7):1010-3. PubMed ID: 17487901
[No Abstract] [Full Text] [Related]
10. Competitive inhibitors of Helicobacter pylori type II dehydroquinase: synthesis, biological evaluation, and NMR studies.
Sánchez-Sixto C; Prazeres VF; Castedo L; Suh SW; Lamb H; Hawkins AR; Cañada FJ; Jiménez-Barbero J; González-Bello C
ChemMedChem; 2008 May; 3(5):756-70. PubMed ID: 18200648
[TBL] [Abstract][Full Text] [Related]
11. Crystallization of a type II dehydroquinase from Mycobacterium tuberculosis.
Gourley DG; Coggins JR; Isaacs NW; Moore JD; Charles IG; Hawkins AR
J Mol Biol; 1994 Aug; 241(3):488-91. PubMed ID: 8064862
[TBL] [Abstract][Full Text] [Related]
12. Determination of the stereochemistry of 2-succinyl-5-enolpyruvyl-6-hydroxy-3- cyclohexene-1-carboxylate, a key intermediate in menaquinone biosynthesis.
Jiang M; Chen M; Cao Y; Yang Y; Sze KH; Chen X; Guo Z
Org Lett; 2007 Nov; 9(23):4765-7. PubMed ID: 17956107
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of Helicobacter pylori type II dehydroquinase inhibitor complexes: new directions for inhibitor design.
Robinson DA; Stewart KA; Price NC; Chalk PA; Coggins JR; Lapthorn AJ
J Med Chem; 2006 Feb; 49(4):1282-90. PubMed ID: 16480265
[TBL] [Abstract][Full Text] [Related]
14. Understanding the key factors that control the inhibition of type II dehydroquinase by (2R)-2-benzyl-3-dehydroquinic acids.
Peón A; Otero JM; Tizón L; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Gago F; Castedo L; González-Bello C
ChemMedChem; 2010 Oct; 5(10):1726-33. PubMed ID: 20815012
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of new nanomolar competitive inhibitors of Helicobacter pylori type II dehydroquinase. Structural details of the role of the aromatic moieties with essential residues.
Prazeres VF; Tizón L; Otero JM; Guardado-Calvo P; Llamas-Saiz AL; van Raaij MJ; Castedo L; Lamb H; Hawkins AR; González-Bello C
J Med Chem; 2010 Jan; 53(1):191-200. PubMed ID: 19911771
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric synthesis of the putative structure of (-)-oryzoxymycin.
Bunnage ME; Ganesh T; Masesane IB; Orton D; Steel PG
Org Lett; 2003 Feb; 5(3):239-42. PubMed ID: 12556161
[TBL] [Abstract][Full Text] [Related]
17. Rational design of new bifunctional inhibitors of type II dehydroquinase.
Toscano MD; Stewart KA; Coggins JR; Lapthorn AJ; Abell C
Org Biomol Chem; 2005 Sep; 3(17):3102-4. PubMed ID: 16106291
[TBL] [Abstract][Full Text] [Related]
18. Progress in type II dehydroquinase inhibitors: from concept to practice.
González-Bello C; Castedo L
Med Res Rev; 2007 Mar; 27(2):177-208. PubMed ID: 17004270
[TBL] [Abstract][Full Text] [Related]
19. Structural investigation of inhibitor designs targeting 3-dehydroquinate dehydratase from the shikimate pathway of Mycobacterium tuberculosis.
Dias MV; Snee WC; Bromfield KM; Payne RJ; Palaninathan SK; Ciulli A; Howard NI; Abell C; Sacchettini JC; Blundell TL
Biochem J; 2011 Jun; 436(3):729-39. PubMed ID: 21410435
[TBL] [Abstract][Full Text] [Related]
20. Determination of the bound conformation of a competitive nanomolar inhibitor of mycobacterium tuberculosis type II dehydroquinase by NMR spectroscopy.
Prazeres VF; Sánchez-Sixto C; Castedo L; Canales A; Cañada FJ; Jiménez-Barbero J; Lamb H; Hawkins AR; González-Bello C
ChemMedChem; 2006 Sep; 1(9):990-6. PubMed ID: 16952136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
